Recombinant epidermal growth factor - Bharat Biotech

Drug Profile

Recombinant epidermal growth factor - Bharat Biotech

Alternative Names: hrecEGF - Bharat Biotech; Recombinant human epidermal growth factor - Bharat Biotech; REGEN-D 150; REGEN-D 60; REGEN-D® 10; rhEGF - Bharat Biotech; rhuEGF - Bharat Biotech

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bharat Biotech
  • Class Antiulcers; Growth factors
  • Mechanism of Action Epidermal growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Burns; Diabetic foot ulcer; Wounds

Most Recent Events

  • 21 Mar 2017 Bharat Biotech plans a phase II trial for Foot disorders (Cracked feet) in India (CTRI/2017/03/008000)
  • 06 Mar 2017 Bharat Biotech initiates enrolment in a phase II trial for Foot disorders (Cracked feet) in India (Topical) (CTRI/2017/03/008000)
  • 15 Jul 2005 Launched for Burns (first- and second-degree burns) in India (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top